Skip to main content
Premium Trial:

Request an Annual Quote

Third Wave Shareholders Tender 92 Percent of Shares to Hologic

NEW YORK (GenomeWeb News) – Hologic said today that Third Wave Technologies' shareholders have tendered approximately 45,225,950 shares, or around 92.1 percent of the company’s outstanding stock, as of the close of its initial offering period to acquire Third Wave, which expired last night.
Hologic said that it has begun a subsequent offering period for all remaining shares of Third Wave common stock in order to allow stockholders who have not yet tendered their shares to do so. This subsequent offering period will expire at midnight, EDT, on July 23.
Hologic said that it will pay shareholders the same $11.25 per share price that it offered in the initial offering period.
The company announced its plans to acquire Third Wave for $11.25 per share, or approximately $580 million, in early June.

The Scan

Another Resignation

According to the Wall Street Journal, a third advisory panel member has resigned following the US Food and Drug Administration's approval of an Alzheimer's disease drug.

Novavax Finds Its Vaccine Effective

Reuters reports Novavax's SARS-CoV-2 vaccine is more than 90 percent effective in preventing COVID-19.

Can't Be Used

The US Food and Drug Administration says millions of vaccine doses made at an embattled manufacturing facility cannot be used, the New York Times reports.

PLOS Papers on Frozen Shoulder GWAS, Epstein-Barr Effects on Immune Cell Epigenetics, More

In PLOS this week: genome-wide association study of frozen shoulder, epigenetic patterns of Epstein-Barr-infected B lymphocyte cells, and more.